AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1932973
Drug: Enalapril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (10 mg/day, adjusted between 5 and 40 mg)
Trial: 1932973
Drug: Atenolol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (50 mg/day, adjusted between 25 and 100 mg)
Trial: 6660928
Drug: Megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol acetate (10 mg daily for 10 days, four times a year)
Trial: 6660928
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate (50 mg for 10 days, four times a year)
Trial: 22169947
Drug: Yohimbine HCl
RxNorm normalized name: yohimbine HCl
DrugBank: Yohimbine (DB01392)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yohimbine HCl (α(2)‐adrenergic receptor antagonist) administered 30 min before acquisition
Trial: 22169947
Drug: Propranolol HCl
RxNorm normalized name: propranolol HCl
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propranolol HCl (β‐adrenergic receptor antagonist) administered 90 min before selective reactivation
Trial: 22169947
Drug: Propranolol HCl
RxNorm normalized name: propranolol HCl
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propranolol HCl administered after reactivation of the memory
Trial: 8568287
Drug: bivalent live
RxNorm normalized name: fecal microbiota, live Enema [Rebyota]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bivalent live attenuated influenza A virus vaccine
Trial: 7140133
Drug: 0.2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg/kg IV propranolol
Trial: 7140133
Drug: 3.2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.2 mg/kg oral propranolol
Trial: 7140133
Drug: 0.025 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.025 mg/kg IV timolol
Trial: 7140133
Drug: 0.4 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg/kg oral timolol
Trial: 14646609
Drug: Idazoxan (alpha-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idazoxan (alpha-2 adrenoreceptor antagonist)
Trial: 10383505
Drug: MK‐0966 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK‐0966 250 mg q.d.
Trial: 10383505
Drug: Ibuprofen 800
RxNorm normalized name: ibuprofen 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 800 mg t.d.s.
Trial: 10383505
Drug: Aspirin 650
RxNorm normalized name: aspirin 650 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 650 mg q.d.s.
Trial: 8678131
Drug: Conjugated estrogens
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated estrogens 0.625 mg per day and medroxyprogesterone 2.5 mg per day
Trial: 30037045
Drug: 0 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 g of mixed spices
Trial: 30037045
Drug: 12 g
RxNorm normalized name: PEG-12 GLYCERYL LAURATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 g of mixed spices
Trial: 359255
Drug: Difunisal (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Difunisal (250 mg or 500 mg twice daily for 5 days)
Trial: 359255
Drug: Aspirin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (600 mg four times daily for 5 days)
Trial: 31542737
Drug: Plan Well
RxNorm normalized name: Plan B One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Plan Well Guide decision aid administered to the patient by a facilitator with the SDM present.
Trial: 25577661
Drug: Consistent limb
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consistent limb group (DTaP-IPV-Hib and PCV13 administered to the right leg)
Trial: 25577661
Drug: Alternating limb
RxNorm normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternating limb group (DTaP-IPV-Hib and PCV13 administered to alternating limbs)
Trial: 21292088
Drug: MSBR +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSBR + HGF (intravenous 150 μg/kg per day)
Trial: 17919488
Drug: 40 g
RxNorm normalized name: PEG-40 GLYCERYL STEARATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 g oleic acid (FFA, 1830 kJ)
Trial: 17919488
Drug: 40 g
RxNorm normalized name: PEG-40 GLYCERYL STEARATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 g macadamia oil (TG, 1856 kJ)
Trial: 17919488
Drug: 600 mL
RxNorm normalized name: urinary bag 600 mL-10" MISCELL EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mL 4% milk protein (control, 352 kJ)
Trial: 15490072
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) replacement therapy at a dose of 0.25 U/kg body weight/week for 72 months
Trial: 11876011
Drug: Beclomethasone dipropionate,
RxNorm normalized name: Beclomethasone Dipropionate, compounding powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate, aqueous nasal spray, 400 micrograms per day, administered every 12 hours for 6 weeks
Trial: 8042862
Drug: Topical Acyclovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Acyclovir (ACV) plus 348U87, initiated immediately after UV exposure
Trial: 2665093
Drug: Conservative-functional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative-functional treatment with a newly developed shoe
Trial: 798654
Drug: Daily occlusive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily occlusive applications of butylated hydroxytoluene for 60 days
Trial: 31324213
Drug: Supraglottic airway
RxNorm normalized name: inBreath airway transplant system
DrugBank: inBreath airway transplant system (DB18692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supraglottic airway device (i-gel®)
Trial: 29190604
Drug: Mulberry extract
RxNorm normalized name: MULBERRY EXTRACT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mulberry extract (300 mg/d, twice per day for 12 weeks)
Trial: 22088586
Drug: Combination group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination group (Acupuncture + Plantain and Senna Granule)
Trial: 19318652
Drug: Assistance with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assistance with pain treatment intervention
Trial: 17538804
Drug: Cetaphil Moisturizing
RxNorm normalized name: Cetaphil Moisturizing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetaphil Moisturizing Cream applied twice daily for 15 days on one half of the face
Trial: 12609480
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (4 matched postmenopausal women without MPA treatment)
Trial: 8622116
Drug: Isepamicin (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isepamicin (15 mg/kg or 8 mg/kg once daily; 7.5 mg/kg twice daily; 4 mg/kg twice daily)
Trial: 6218099
Drug: Mezlocillin (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mezlocillin (16 g daily)
Trial: 6218099
Drug: Carbenicillin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbenicillin (30 g daily)
Trial: 26923301
Drug: Standard blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard blood infusion set (control)
Trial: 8547209
Drug: Ramipril (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril (mean dose 8 mg)
Trial: 7048826
Drug: Urokinase (200,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urokinase (200,000 Ploug units during the first 24 hours) followed by heparin (40,000 units daily for 5 days)
Trial: 7048826
Drug: Heparin (40,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (40,000 units daily for 6 days)
Trial: 28205258
Drug: Antofloxacin hydrochloride
RxNorm normalized name: danofloxacin
DrugBank: Danofloxacin (DB11393)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antofloxacin hydrochloride 200 mg IV
Trial: 26637583
Drug: 100 μg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 μg/mL of AMB nasal irrigation daily for 2 months
Trial: 26637583
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (NS) solution nasal irrigation daily for 2 months
Trial: 19474650
Drug: DRV/r (darunavir/ritonavir)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DRV/r (darunavir/ritonavir) 600/100 mg twice daily
Trial: 12692749
Drug: ACE inhibitor
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitor (lisinopril, 20 mg o.d. for two years)
Trial: 9888904
Drug: Teaching patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teaching patients to identify early symptoms of relapse and seek prompt treatment from health services (7 to 12 individual treatment sessions from a research psychologist plus routine care)
Trial: 9888904
Drug: Teaching patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teaching patients to identify early symptoms of relapse and seek prompt treatment from health services
Trial: 7741619
Drug: Control patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control patch (not activated)
Trial: 7102768
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of oral sulpiride for 4 days from the third postpartum day
Trial: 8092084
Drug: 0.80 g
RxNorm normalized name: Niacinamide 0.80 g in 40 mL / Adenosine 0.01 g in 40 mL TOPICAL LIQUID [AAPE Continuous Renewal Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.80 g protein.kg‐1.d‐1
Trial: 8092084
Drug: 1.62 g
RxNorm normalized name: Brioschi 1.8 GM / 1.62 GM Granules for Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.62 g protein.kg‐1.d‐1
Trial: 12869382
Drug: Therapeutic infusions
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic infusions of immunoglobulins (Ig)
Trial: 12869382
Drug: In vitro
RxNorm normalized name: glucuronidase in vitro test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In vitro with RBC suspensions containing fibrinogen, albumin, and Ig
Trial: 9094145
Drug: Selegiline (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selegiline (both doses)
Trial: 3113244
Drug: misoprostol 200
RxNorm normalized name: MISOPROSTOL 200MCG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: misoprostol 200 micrograms twice daily
Trial: 29520867
Drug: Phenylephrine 50
RxNorm normalized name: phenylephrine 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine 50 μg
Trial: 29520867
Drug: Ephedrine 4
RxNorm normalized name: ephedrine 48 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine 4 mg
Trial: 28794283
Drug: Proinsulin peptide
RxNorm normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proinsulin peptide immunotherapy (intradermally every 2 or 4 weeks for 6 months)
Trial: 9296310
Drug: Temocapril (10-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temocapril (10-40 mg once daily)
Trial: 9296310
Drug: Atenolol (25-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (25-100 mg once daily)
Trial: 7982016
Drug: Inosine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inosine (1.5 g daily, 3 x 500 mg for 6 weeks)
Trial: 3722507
Drug: 0.1% topical
RxNorm normalized name: Halog 0.1% Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% topical minoxidil
Trial: 3722507
Drug: 0.01% topical
RxNorm normalized name: Retin-A 0.01% Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.01% topical minoxidil
Trial: 30055593
Drug: Practicing self‐medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Practicing self‐medication
Trial: 24971565
Drug: Palivizumab prophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palivizumab prophylaxis (6 consecutive monthly doses)
Trial: 15930349
Drug: ABI-007 (260
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABI-007 (260 mg/m², 30 minutes; n = 14)
Trial: 15930349
Drug: Taxol (175
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taxol (175 mg/m², 3 hours; n = 13)
Trial: 10795956
Drug: Standard Treatment
RxNorm normalized name: Azo-Standard
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard Treatment (ST, n = 61)
Trial: 8447204
Drug: Low-dose adenosine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose adenosine (30 micrograms.kg‐1.min‐1 for 4 hours)
Trial: 8447204
Drug: Low-dose adenosine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose adenosine
Trial: 3082450
Drug: Completion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Completion of treatment programme and attendance at all follow up visits
Trial: 29282948
Drug: Ultrasound guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound guided injection group
Trial: 29282948
Drug: Palpation guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palpation guided injection group
Trial: 21095483
Drug: lersivirine 500
RxNorm normalized name: Lersivirine
DrugBank: Lersivirine (DB11649)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lersivirine 500 mg BID
Trial: 21095483
Drug: lersivirine 750
RxNorm normalized name: Lersivirine
DrugBank: Lersivirine (DB11649)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lersivirine 750 mg once daily
Trial: 1990191
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of acyclovir orally two times per day (suppressive therapy)
Trial: 1990191
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of acyclovir five times per day for 5 days (for recurrences)
Trial: 1990191
Drug: Daily acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily acyclovir therapy (suppressive therapy)
Trial: 1990191
Drug: Acute therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute therapy followed by suppressive therapy
Trial: 30571697
Drug: Talking Prescriptions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Talking Prescriptions (Talking Rx) intervention including Daily Interactive Voice Response (IVR) call services, Daily tailored medication reminders, and Weekly lifestyle modification messages for 3 months.
Trial: 30571697
Drug: Talking Prescriptions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Talking Prescriptions (Talking Rx) intervention for CVA patients.
Trial: 22490713
Drug: High-dose tirofiban
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose tirofiban (25 µg/kg bolus followed by 0.15 µg×kg(‐1)×min(‐1) infusion for 36 hours, n = 40)
Trial: 22490713
Drug: Standard-dose tirofiban
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose tirofiban (10 µg/kg bolus followed by 0.15 µg×kg(‐1)×min(‐1) infusion for 36 hours, n = 40)
Trial: 20169258
Drug: Intra-articular administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular administration of 10 mg of morphine
Trial: 20169258
Drug: Intra-articular administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular administration of 20 mL of NS
Trial: 10460042
Drug: Testosterone transscrotal
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone transscrotal patch (6 mg/day)
Trial: 8546997
Drug: Twice-weekly MPD-PUVA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly MPD-PUVA
Trial: 8546997
Drug: Three times-weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three times-weekly skin typing-PUVA
Trial: 318984
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg LOX
Trial: 318984
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg LOX
Trial: 31339826
Drug: Rituximab maintenance
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab maintenance (375 mg/m2, once every 8 weeks for 2 years)
Trial: 31339826
Drug: Observation (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observation (no additional treatment)
Trial: 26521572
Drug: Head-point needle-retaining
RxNorm normalized name: Head & Shoulders
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Head-point needle-retaining therapy + training (group A)
Trial: 19220493
Drug: Ritonavir-boosted protease
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ritonavir-boosted protease inhibitors
Trial: 19220493
Drug: Nonnucleoside reverse
RxNorm normalized name: OraVerse
DrugBank: Phentolamine (DB00692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nonnucleoside reverse transcriptase inhibitors (NNRTIs), particularly efavirenz
Trial: 11338761
Drug: Aloe vera
RxNorm normalized name: ALOE VERA
DrugBank: Aloe vera leaf (DB13906)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aloe vera gel/mild soap
Trial: 10210991
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human growth hormone (rhGH) treatment in prepubertal children
Trial: 10210991
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human growth hormone (rhGH) treatment in pubertal children
Trial: 3356152
Drug: Antiepileptic drug
RxNorm normalized name: ANTIEPILEPTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiepileptic drug study with centralized case validation system
Trial: 23877864
Drug: Remifentanil 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 4 µg/kg intravenously
Trial: 20375299
Drug: GIN therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GIN therapy (insulin at 2 mU . kg(‐1) . min(‐1) during surgery, decreased to 1 mU . kg(‐1) . min(‐1) for 24 hours, dextrose 20% infusion)
Trial: 20375299
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (conventional insulin sliding scale)
Trial: 21757376
Drug: GIN therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GIN therapy
Trial: 31786872
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy combined with interval cytoreductive surgery
Trial: 29188298
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus RT (2 cycles of gemcitabine 1000 mg/m2 on days 1, 8, and 15, and cisplatin 70 mg/m2 on day 2, followed by RT to 4500 cGy in 150 cGy twice-daily fractions over 3 weeks)
Trial: 29188298
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (4 cycles of gemcitabine and cisplatin)
Trial: 29188298
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus RT
Trial: 27075990
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received a similarly timed sham treatment.
Trial: 22093057
Drug: Testosterone undecanoate
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone undecanoate 1000 mg
Trial: 19799810
Drug: Induction-concurrent chemoradiotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction-concurrent chemoradiotherapy (IC/CCRT)
Trial: 19799810
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy and radiotherapy (IC/RT)
Trial: 15716206
Drug: Intravesical hyaluronic
RxNorm normalized name: hyaluronate
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravesical hyaluronic acid therapy (40 mg weekly for 10 weeks)
Trial: 15716206
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (C(max) <350 cc)
Trial: 15716206
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (C(max) >/=350 cc)
Trial: 8719069
Drug: VIP chemotherapy
RxNorm normalized name: VIP
DrugBank: Vasoactive intestinal peptide (DB18634)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VIP chemotherapy (vindesine 3 mg/m2 days 1 and 8, ifosfamide 1200 mg/m2, cisplatin 30 mg/m2 days 1, 2 and 3, repeated every 4 weeks, up to six cycles)